Hallmarks of pancreatic cancer: spotlight on TAM receptors
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Vázquez-Bellón, Núria
- dc.contributor.author Martínez Bosch, Neus
- dc.contributor.author García de Frutos, Pablo
- dc.contributor.author Navarro Medrano, Pilar
- dc.date.accessioned 2025-04-24T06:11:55Z
- dc.date.available 2025-04-24T06:11:55Z
- dc.date.issued 2024
- dc.description.abstract Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.
- dc.description.sponsorship This work was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) (PI20/00625 and PI23/00591) to PN, 8th “Beca Carmen Delgado” to PN and PGF and grants from the MICIU (PID2021-123564OB-100) to PGF. The funders did not have any role in paper design, data collection, data analysis, interpretation, or writing of the paper. NV-B is supported by a FPU (“Formación de Profesorado Universitario”) predoctoral contract from the MICIU (FPU21/0928). The authors did not receive remuneration for their participation. We thank TPM Science for English proofreading and manuscript editing.
- dc.format.mimetype application/pdf
- dc.identifier.citation Vázquez-Bellón N, Martínez-Bosch N, García de Frutos P, Navarro P. Hallmarks of pancreatic cancer: spotlight on TAM receptors. EBioMedicine. 2024 Sep;107:105278. DOI: 10.1016/j.ebiom.2024.105278
- dc.identifier.doi http://dx.doi.org/10.1016/j.ebiom.2024.105278
- dc.identifier.issn 2352-3964
- dc.identifier.uri http://hdl.handle.net/10230/70184
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof EBioMedicine. 2024 Sep;107:105278
- dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2021-123564OB-100
- dc.rights © 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Diagnosis
- dc.subject.keyword PDAC
- dc.subject.keyword Pancreatic cancer
- dc.subject.keyword TAM receptors
- dc.subject.keyword Treatment
- dc.title Hallmarks of pancreatic cancer: spotlight on TAM receptors
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion